Literature DB >> 12416642

Classification for congenital anomalies of the hand: the IFSSH classification and the JSSH modification.

L De Smet1.   

Abstract

The purpose of a classification for clinical problems which, except for a few specialized centers, occur only sporadically is to provide a system where these cases can be stored. This should allow all involved investigators to speak the same language; so-doing syndromes can be delinated, frequencies of occurence established and results of--different--treatments compared. A classification system should be simple to use, reliable and uniformly accepted. It should allow space for adaptations and/or extensions. The IFSSH proposed a 7 categories classification based on the proposed classification of Swanson et al. in 1976. This classification, was based on, which was thought in the seventies, etiopathogenic pathways. These 7 groups are: I. Failure of formation; transverse (A), or longitudinal (B) II. Failure of differentiation III. Polydactyly IV. Overgrowth V. Undergrowth VI. Amniotic band syndrome VII. Generalized skeletal syndromes. The extended classification proposed by IFSSH was used to classify 1013 hand differences in 925 hands of 650 patients. We found associated anomalies in 26.7%. The classification was straightforward in 86%, difficult in 6.6% and not possible in 7.8%. Group II was the most numerous group including 513 anomalies. We propose to include in this group the Madelung deformity, the Kirner deformity and congenital trigger fingers and trigger thumbs. In group I the radial and ulnar deficiencies, limited to the hand without forearm deficlencies should be Included. Triphalangeal thumbs are a problem, we suggest it to be listed in group III and consider it as a duplication in length. It is not always possible to evaluate the (transverse) absence of the fingers or hand. Longitudinal deficiencies (group IIB), symbrachydactyly (group V), and amniotic bands (group IV) occasionally develop a phenotype similar to the genuine transverse deficiency (group IA). Recently, the Japanese Society for Surgery of the Hand (JSSH) (16) proposed an extension/modification of the IFSSH classification. Based on newer knowledge on teratology, symbrachydactyly in all stages were transfered to group I. Two new groups were introduced. A group "failure of finger ray induction" including typical cleft hand (IC), central polydactyly (III) and (bony) syndactyly (II)--was included. Also a group of "unclassifiable" cases was added. This Japanese proposed classification is a real improvement and most clinicians and surgeons tend to use it in the future.

Entities:  

Mesh:

Year:  2002        PMID: 12416642

Source DB:  PubMed          Journal:  Genet Couns        ISSN: 1015-8146


  6 in total

1.  A new documentation system for congenital absent digits.

Authors:  Neil F Jones; Jesse Kaplan
Journal:  Hand (N Y)       Date:  2012-12

2.  Inflammatory conditions of the pediatric hand and non-inflammatory mimics.

Authors:  Leanne N Royle; Bernadette W Muthee; Daniel G Rosenbaum
Journal:  Pediatr Radiol       Date:  2021-08-20

3.  CASE STUDY OF CONGENITAL ANOMALIES OF THE UPPER LIMB IN REFERENCE AMBULATORY CARE FACILITY.

Authors:  Henrique de Barros Pinto; Antônio Pedro Pais; Simone Costa Vitorio; Renata Brandão; Aline Aparecida Depianti Moreira; Luiz Raphael Molinaro
Journal:  Acta Ortop Bras       Date:  2018       Impact factor: 0.513

Review 4.  Congenital differences of the upper extremity: classification and treatment principles.

Authors:  Moon Sang Chung
Journal:  Clin Orthop Surg       Date:  2011-08-19

5.  Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans.

Authors:  Amira Elmakky; Ilaria Stanghellini; Antonio Landi; Antonio Percesepe
Journal:  Curr Genomics       Date:  2015-08       Impact factor: 2.236

6.  A morpho-etiological description of congenital limb anomalies.

Authors:  S M Tayel; M M Fawzia; Niran A Al-Naqeeb; Said Gouda; S A Al Awadi; K K Naguib
Journal:  Ann Saudi Med       Date:  2005 May-Jun       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.